Cancer specific vaccine therapy using HLA-A24 restricted epitope-peptide for patients with advanced metastatic colorectal cancer.PhaseI/II clinical trial.

Cancer specific vaccine therapy using HLA-A24 restricted epitope-peptide for patients with advanced metastatic colorectal cancer.PhaseI/II clinical trial. - Cancer peptide vaccine for advanced metastatic cancer.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004994

Enrollment

Registered

2011-02-10

Start date

2011-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal cancer

Interventions

Subctaneus injection of cancer peptide vaccine(three peptides)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 Standard therapies failured 2 Performance status 0-1 3 Lesions identifiable with images 4 More than 4 weeks after previous therapy 5 Prognosis no less than 3 months 6 WBC 2000 -15000, Platelet =>50000, GOT, GPT =<150, Cr =< 3.0 TB =< 3.0 7 HLA-A24 positive 8 Written informed consent

Exclusion criteria

Exclusion criteria: 1 Expectant 2 During lactation 3 possible expectant women 4 Active infectious diseases 5 Systemic use of steroid hormones or immunosuppressive drugs 6 Others (Doctors judges)

Design outcomes

Primary

Measure	Time frame
Safety Overall survival	—

Secondary

Measure	Time frame
Immunological responce(in vitro CTL induction) Responsiveness(tumor size)	—

Countries

Japan

Contacts

Public ContactYasuo Takahashi

Hokkaido Cancer Center Gastroenterology

takahasi@sap-cc.go.jp011-811-9111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026